InnoCan Pharma Statistics

Total Valuation

InnoCan Pharma has a market cap or net worth of CAD 52.64 million. The enterprise value is 48.11 million.

Market Cap	52.64M
Enterprise Value	48.11M

Important Dates

The last earnings date was Monday, March 31, 2025.

Earnings Date	Mar 31, 2025
Ex-Dividend Date	n/a

Share Statistics

InnoCan Pharma has 292.42 million shares outstanding. The number of shares has increased by 8.96% in one year.

Current Share Class	n/a
Shares Outstanding	292.42M
Shares Change (YoY)	+8.96%
Shares Change (QoQ)	+1.91%
Owned by Insiders (%)	3.90%
Owned by Institutions (%)	0.18%
Float	231.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.24
PB Ratio	5.21
P/TBV Ratio	7.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-18.23
EV / Sales	1.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-20.98

Financial Position

The company has a current ratio of 4.09, with a Debt / Equity ratio of 0.00.

Current Ratio	4.09
Quick Ratio	2.48
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage	-178.14

Financial Efficiency

Return on equity (ROE) is -4.59% and return on invested capital (ROIC) is -13.61%.

Return on Equity (ROE)	-4.59%
Return on Assets (ROA)	-9.62%
Return on Invested Capital (ROIC)	-13.61%
Return on Capital Employed (ROCE)	-17.76%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	3.63
Inventory Turnover	1.28

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.33% in the last 52 weeks. The beta is 3.01, so InnoCan Pharma's price volatility has been higher than the market average.

Beta (5Y)	3.01
52-Week Price Change	-33.33%
50-Day Moving Average	0.19
200-Day Moving Average	0.21
Relative Strength Index (RSI)	47.83
Average Volume (20 Days)	24,141

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCan Pharma had revenue of CAD 42.36 million and -2.64 million in losses. Loss per share was -0.01.

Revenue	42.36M
Gross Profit	37.68M
Operating Income	-1.79M
Pretax Income	1.32M
Net Income	-2.64M
EBITDA	-1.74M
EBIT	-1.79M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 7.21 million in cash and 14,388 in debt, giving a net cash position of 7.19 million or 0.02 per share.

Cash & Cash Equivalents	7.21M
Total Debt	14,388
Net Cash	7.19M
Net Cash Per Share	0.02
Equity (Book Value)	10.10M
Book Value Per Share	0.03
Working Capital	9.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.27 million and capital expenditures -21,583, giving a free cash flow of -2.29 million.

Operating Cash Flow	-2.27M
Capital Expenditures	-21,583
Free Cash Flow	-2.29M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 88.96%, with operating and profit margins of -4.24% and -6.23%.

Gross Margin	88.96%
Operating Margin	-4.24%
Pretax Margin	3.12%
Profit Margin	-6.23%
EBITDA Margin	-4.12%
EBIT Margin	-4.24%
FCF Margin	n/a

Dividends & Yields

InnoCan Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.96%
Shareholder Yield	-8.96%
Earnings Yield	-5.01%
FCF Yield	-4.36%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

InnoCan Pharma has an Altman Z-Score of 12.63.

Altman Z-Score	12.63
Piotroski F-Score	n/a